Leighl NB, Hellmann MD, Hui R, et al. KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab. J Clin Oncol. 35, 2017 (suppl; abstr 9011).
Congressen IGCA en ESDE: beide geslaagd, en ook verbinding
jul 2025 | Maag-darm-leveroncologie